Marek Trněný, MD, PhD of the Charles University, Prague, Czech Republic discusses trials and research in mantle cell lymphoma (MCL) that he is involved in. On the research side, Prof. Trněný explains that they are trying to analyze the molecular changes and the cytogenetic changes and their impact on outcome in mantle cell lymphoma. He points out that cytogenetics is a field that some people would like to ignore but it can provide important data. Further, they have a number of mouse models, which they are studying with new compounds. In terms of the clinical perspective, they have published the SPRINT trial of lenalidomide (NCT00875667) and he further mentions that they run a comprehensive, prospective database of patients in the Czech Republic. Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.